Pemetinib, a new option for cholangiocarcinoma, drug information and dosage guidelines

Pemigatinib (Pemigatinib), known by the trade name Pemazyre, is a small molecule kinase inhibitor carefully developed by Incyte Corporation. This drug was jointly developed by Incyte and Innovent Biologics, and commercialized and promoted by Innovent Biologics in mainland China, Hong Kong, Macau and Taiwan. As the first selective FGFR receptor tyrosine kinase inhibitor approved in China, pemetinib is mainly targeted at the treatment of cholangiocarcinoma and relapsed or refractory myeloid or lymphoid tumors (MLNs).

Pemetinib is indicated for adults with advanced, metastatic or unresectable cholangiocarcinoma who have undergone at least one systemic therapy and have been tested to confirm the presence of FGFR2 fusions or rearrangements. Its mechanism of action is to inhibit the phosphorylation and signaling of FGFR1, FGFR2, FGFR3 and FGFR4, thereby inhibiting the proliferation and survival of tumor cells.

The drug is available in tablet form, available in 4.5mg, 9mg and 13.5mg strengths. The recommended dosage is 13.5 mg once a day, taken for 14 days and then stopped for 7 days, forming a complete 21-day treatment cycle. Patients are advised to take it at approximately the same time each day, either on an empty stomach or with food. Tablets should be swallowed whole and should not be crushed, chewed, cut or dissolved before taking. If you miss a dose for more than 4 hours or vomit after taking the medicine, there is no need to take a supplementary dose. Just continue to take the prescribed dose according to the next dose time.

Pemetinib has shown good efficacy and safety in the treatment of cholangiocarcinoma. However, like all medications, it may cause side effects such as diarrhea, nausea, taste changes, vomiting, loss of appetite, fatigue, joint pain, blurred vision, etc. Patients should contact their doctor immediately if they experience any discomfort or side effects.

Prior to treatment with pemetinib, patients need to confirm the presence of FGFR2 fusions or rearrangements through validated testing methods In addition, patients should undergo regular blood tests and eye examinations during treatment to ensure the safety and effectiveness of the drug.

Taken together, pemetinib provides a new treatment option for patients with cholangiocarcinoma, especially when current treatment options are limited. However, patients must strictly follow the doctor's instructions when using it, pay attention to the correct usage and dosage of the drug, and pay close attention to possible side effects. Currently, there are different versions of this drug on the market with different prices, and patients can make a choice based on their own circumstances.